**Sir,**

The activating E17K mutations recently discovered in the pleckstrin homology domain of *AKT1* in about 2% of endometrial cancer patients ([Shoji *et al*, 2009](#bib10){ref-type="other"}) suggest a new mechanism for PI3 kinase pathway activation in these patients, as previously described in breast, colorectal and ovarian cancers ([Carpten *et al*, 2007](#bib1){ref-type="other"}). Additional mechanisms of PI3 kinase pathway activation in endometrial cancer include the somatic mutation of *PTEN* and *PIK3CA* ([Kong *et al*, 1997](#bib6){ref-type="other"}; [Oda *et al*, 2005](#bib8){ref-type="other"}), amplification and overexpression of *PIK3CA* ([Miyake *et al*, 2008](#bib7){ref-type="other"}; [Salvesen *et al*, 2009](#bib9){ref-type="other"}), and decreased expression of *PTEN* ([Kanamori *et al*, 2001](#bib4){ref-type="other"}; [Kappes *et al*, 2001](#bib5){ref-type="other"}).

We found an additional four mutations in AKT family members ([Table 1](#tbl1){ref-type="table"}). Two of these (mutations in the catalytic domain of *AKT2* (D399N) and the regulatory domain of *AKT3* (E438D)) were previously reported in a sequencing screen of 123 genes in 41 primary endometrial cancers ([Dutt *et al*, 2008](#bib2){ref-type="other"}). Manual reinspection of these data in light of the report on activating *AKT1* mutations in endometrial cancer ([Shoji *et al*, 2009](#bib10){ref-type="other"}) revealed an additional mutation, *AKT1* E17K, identical to the one reported by [Shoji *et al* (2009](#bib10){ref-type="other"}), and a novel mutation in the catalytic domain of *AKT2* (R368C) in two additional samples. We validated these mutations as somatic by mass spectrometric genotyping of the tumour and matched normal DNA, after an independent PCR amplification. We also found a novel candidate mutation in the pleckstrin homology domain of *AKT2* (D32H), which we could not validate because of insufficient DNA. All these mutations occurred in cancers of the endometrioid subtype that had no signs of metastasis either at primary treatment or during follow-up. Taken together, we find that 5 out of 41 endometrial cancers have mutations in AKT family members for a 12% rate.

Confirmation that these novel mutations activate the PI3 kinase pathway awaits their functional characterisation. Notably, all the AKT family member mutations found in our data occur at residues conserved across multiple species (see [Supplementary Figure 1](#sup1){ref-type="other"}). However, three of these five mutations were identified in samples harbouring mutations of *PTEN*, one of which also had amplification of and a mutation in *PIK3CA* ([Table 1](#tbl1){ref-type="table"}); the *AKT1* E17K mutation is not associated with either *PTEN* or *PIK3CA* genomic alteration. It is therefore possible that these AKT family mutations have different functional effects from mutations of *PTEN* and *PIK3CA*. Given the importance of the PI3 kinase pathway in endometrial cancer oncogenesis ([Salvesen *et al*, 2009](#bib9){ref-type="other"}), and the emerging therapeutic options for PI3 kinase inhibition ([Garcia-Echeverria and Sellers, 2008](#bib3){ref-type="other"}), the functional effects of all these AKT family mutations should be investigated in appropriate model systems of endometrial cancer.

Supplementary Material {#sup1}
======================

###### Supplementary Figure 1

###### Supplementary Figure Legend

[Supplementary Information](#sup1){ref-type="other"} accompanies the paper on British Journal of Cancer website (<http://www.nature.com/bjc>)

###### 

AKT family mutations found in endometrial cancer

  **Gene**   **Sample ID**   **Mutation**   **Domain**               **PIK3CA amplification**^**a**^  **Other mutations**
  ---------- --------------- -------------- ----------------------- --------------------------------- -----------------------------
  AKT1       436T            E17K           Pleckstrin homology                    No                 KRAS (G13D)
  AKT2       288T            D399N          Regulatory C-terminal                  No                 PTEN (D24Y, F341Y, R130Q)
  AKT2       426T            R368C          Catalytic kinase                       No                 CTNNB1 (S37Y)
  AKT2       141T            D32H^b^        Pleckstrin homology                    No                 PTEN (R130Q)
  AKT3       192T            E438D          Regulatory C-terminal                  Yes                PTEN (R130Q), PIK3CA (R88Q)

Determined by segmentation analysis of normalised signal intensities from 100K single-nucleotide polymorphism arrays as previously reported ([Salvesen *et al*, 2009](#bib9){ref-type="other"}).

Candidate mutation not validated by mass spectrometric genotyping.
